Amiram Goldblum

Title: The Innovative Mind of Amiram Goldblum

Introduction

Amiram Goldblum, an accomplished inventor based in Tel Aviv, Israel, has made significant strides in the field of pharmaceutical innovations. With two notable patents to his name, Goldblum's work has the potential to greatly enhance therapeutic practices.

Latest Patents

Among his latest patents, Goldblum has developed agonists of PPAR-δ. These PPAR receptor modulators were discovered through a chemoinformatics-based model, emphasizing their usefulness in medical applications. His research focuses on creating novel agonists for PPAR-δ which hold promise for various therapeutic uses. Another patented innovation is liposomal mupirocin. This invention features liposomes encapsulating mupirocin, designed for improved systemic therapeutically effective delivery. The formulation includes a lipid membrane and an intraliposomal compartment containing mupirocin, a cyclodextrin compound, and a pH-dependent ionizable anion, such as acetate. This advancement offers new potentials in pharmaceutical compositions and methodologies.

Career Highlights

Goldblum has been associated with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., marking a prominent part of his career. His contribution to the field is underscored by his dedication to advancing medical technology and drug delivery systems.

Collaborations

Throughout his career, Goldblum has collaborated with notable colleagues including Yechezkel Barenholz and Ahuva Cern. Their partnerships reflect a collective effort towards pioneering research and innovative solutions in the pharmaceutical domain.

Conclusion

Amiram Goldblum's contributions to innovation in pharmaceutical technology are marked by his inventive patents and successful collaborations. With a strong foundation in research and development, his work continues to inspire advancements that could reshape medical treatments, benefitting patients and healthcare professionals alike.